Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 Plus Nab-Paclitaxel and Cadonilimab for Gastric-Type Cervical Adenocarcinoma
NCT06654011Phase 2Recruiting
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifebemtinib and cadonilimab in Gastric-Type Adenocarcinoma Of The Cervix (GAS). Primary endpoint: Objective Response Rate at 18 weeks. Started Feb 2025; status: recruiting.
02
Drugs
ifebemtinibcadonilimab
03
Conditions
Gastric-Type Adenocarcinoma Of The Cervix (GAS)
Beyond the preview
Go deeper on NCT06654011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654011.